In a patient with impaired renal function and a multidrug‑resistant organism infection, should colistin be administered with a loading dose or without a loading dose?

Colistin Loading Dose in Renal Impairment with MDRO Infections

A loading dose of colistin should be administered to patients with impaired renal function and multidrug-resistant organism infections, regardless of their renal status, as the loading dose is essential to rapidly achieve therapeutic plasma concentrations and is not eliminated renally.

Rationale for Loading Dose in Renal Dysfunction

The pharmacokinetics of colistin methanesulfonate (CMS) create a critical therapeutic challenge: CMS must convert to active colistin in vivo, a process that takes 2-3 days to reach steady-state concentrations without a loading dose 1. This delay in achieving therapeutic levels occurs regardless of renal function because the loading dose distributes into tissues rather than being immediately eliminated 1.

Multiple guidelines consistently recommend:

• Loading dose: 6-9 million IU (MIU) of CMS 1
• The most recent 2022 guideline specifies 9 MIU (5 mg/kg) loading dose 2
• Critically important: The loading dose should be administered in all patients including those with renal dysfunction 1

Dosing Algorithm

Step 1: Administer Loading Dose

• Give 6-9 MIU regardless of creatinine clearance 1
• Administer slowly over 3-5 minutes 3
• Do not reduce the loading dose for renal impairment 1

Step 2: Adjust Maintenance Dose Based on Renal Function

After the loading dose, maintenance dosing must be individualized:

For CrCl ≥50 mL/min:

• 4.5 MIU every 12 hours 2, 1

For CrCl 30-49 mL/min:

• 2.5 MIU once daily or divided into 2 doses 3

For CrCl 10-29 mL/min:

• 1.5 MIU every 36 hours 3

For continuous renal replacement therapy (CRRT):

• At least 9 MIU/day total 1
• Normal loading dose still applies 1

For intermittent hemodialysis:

• Normal loading dose (6-9 MIU) 1
• Maintenance: 2 MIU every 12 hours 1
• Time dialysis toward end of dosing interval 1

Critical Safety Considerations

Nephrotoxicity Monitoring

• Monitor renal function closely during therapy 2 - this is a strong recommendation despite low-quality evidence
• Acute kidney injury is a major factor related to clinical failure and mortality 2
• Patients with pre-existing chronic kidney disease or elderly patients face higher risk 2

Common Pitfall to Avoid

The most dangerous error is withholding or reducing the loading dose in patients with renal impairment. This leads to suboptimal plasma concentrations for 2-3 days, which is associated with higher mortality 1. The loading dose distributes into body compartments and is not immediately subject to renal elimination, making it safe and necessary even in severe renal dysfunction 1.

Evidence Quality and Nuances

The recommendation for loading doses comes from pharmacokinetic studies demonstrating that without a loading dose, colistin concentrations remain subtherapeutic for days 1. One key study by Plachouras et al. showed plasma colistin concentrations were sub-optimal for 2-3 days before reaching steady state in critically ill patients receiving standard dosing without a loading dose 1.

The evidence consistently shows across all guidelines (2015 and 2022) that the loading dose should not be adjusted for renal function 1. Only maintenance doses require adjustment based on creatinine clearance 2, 1, 3.

Recent research confirms that colistin exposure cannot be predicted solely from renal function, and therapeutic drug monitoring may assist in individualized dosing 4. However, in the absence of therapeutic drug monitoring, following the guideline-based loading dose approach remains the standard of care.